An evaluation of antibiotic options for the treatment of biothreat pathogens
The development of medical countermeasures against pathogens of biodefense concern remains critical to protecting military and public health. This review compares data detailing antibacterial activity and efficacy for a selection of antibiotics evaluated against potential bacterial biothreat pathoge...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Antibiotics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frabi.2025.1611588/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849404395874156544 |
|---|---|
| author | J. Matthew Meinig Michelle Nelson Christopher K. Cote Stevan R. Emmett Sarah V. Harding Sarah V. Harding |
| author_facet | J. Matthew Meinig Michelle Nelson Christopher K. Cote Stevan R. Emmett Sarah V. Harding Sarah V. Harding |
| author_sort | J. Matthew Meinig |
| collection | DOAJ |
| description | The development of medical countermeasures against pathogens of biodefense concern remains critical to protecting military and public health. This review compares data detailing antibacterial activity and efficacy for a selection of antibiotics evaluated against potential bacterial biothreat pathogens. The human safety and tolerability of these formulations were also considered. This review includes finafloxacin, levofloxacin, delafloxacin, omadacycline, gepotidacin, tebipenem and sulopenem. The selection criteria of these antibiotics were 1) the availability of an oral formulation, 2) the regulatory status (licensed by a regulatory authority or in an advanced stage of development) and 3) the availability of publicly available information on the biodefence pathogens of concern. We hope to highlight approved or advanced clinical candidates that have significant and unique potential in the biodefense space which may be deployed to protect both the public and warfighter against these bacterial infections. |
| format | Article |
| id | doaj-art-3ebfcac4c3e2468fa875c602206d26a1 |
| institution | Kabale University |
| issn | 2813-2467 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Antibiotics |
| spelling | doaj-art-3ebfcac4c3e2468fa875c602206d26a12025-08-20T03:36:59ZengFrontiers Media S.A.Frontiers in Antibiotics2813-24672025-08-01410.3389/frabi.2025.16115881611588An evaluation of antibiotic options for the treatment of biothreat pathogensJ. Matthew Meinig0Michelle Nelson1Christopher K. Cote2Stevan R. Emmett3Sarah V. Harding4Sarah V. Harding5Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United StatesDefence Science and Technology Laboratory, Porton Down, Salisbury, United KingdomBacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United StatesDefence Science and Technology Laboratory, Porton Down, Salisbury, United KingdomDefence Science and Technology Laboratory, Porton Down, Salisbury, United KingdomRespiratory Sciences, University of Leicester, Leicester, United KingdomThe development of medical countermeasures against pathogens of biodefense concern remains critical to protecting military and public health. This review compares data detailing antibacterial activity and efficacy for a selection of antibiotics evaluated against potential bacterial biothreat pathogens. The human safety and tolerability of these formulations were also considered. This review includes finafloxacin, levofloxacin, delafloxacin, omadacycline, gepotidacin, tebipenem and sulopenem. The selection criteria of these antibiotics were 1) the availability of an oral formulation, 2) the regulatory status (licensed by a regulatory authority or in an advanced stage of development) and 3) the availability of publicly available information on the biodefence pathogens of concern. We hope to highlight approved or advanced clinical candidates that have significant and unique potential in the biodefense space which may be deployed to protect both the public and warfighter against these bacterial infections.https://www.frontiersin.org/articles/10.3389/frabi.2025.1611588/fullantibioticsbiodefencemedical countermeasuresantimicrobial susceptibilitybiocontainment |
| spellingShingle | J. Matthew Meinig Michelle Nelson Christopher K. Cote Stevan R. Emmett Sarah V. Harding Sarah V. Harding An evaluation of antibiotic options for the treatment of biothreat pathogens Frontiers in Antibiotics antibiotics biodefence medical countermeasures antimicrobial susceptibility biocontainment |
| title | An evaluation of antibiotic options for the treatment of biothreat pathogens |
| title_full | An evaluation of antibiotic options for the treatment of biothreat pathogens |
| title_fullStr | An evaluation of antibiotic options for the treatment of biothreat pathogens |
| title_full_unstemmed | An evaluation of antibiotic options for the treatment of biothreat pathogens |
| title_short | An evaluation of antibiotic options for the treatment of biothreat pathogens |
| title_sort | evaluation of antibiotic options for the treatment of biothreat pathogens |
| topic | antibiotics biodefence medical countermeasures antimicrobial susceptibility biocontainment |
| url | https://www.frontiersin.org/articles/10.3389/frabi.2025.1611588/full |
| work_keys_str_mv | AT jmatthewmeinig anevaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT michellenelson anevaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT christopherkcote anevaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT stevanremmett anevaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT sarahvharding anevaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT sarahvharding anevaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT jmatthewmeinig evaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT michellenelson evaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT christopherkcote evaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT stevanremmett evaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT sarahvharding evaluationofantibioticoptionsforthetreatmentofbiothreatpathogens AT sarahvharding evaluationofantibioticoptionsforthetreatmentofbiothreatpathogens |